CL2014001263A1 - Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases. - Google Patents

Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.

Info

Publication number: CL2014001263A1
Authority: CL; Chile
Prior art keywords: binding molecule; bcma; cell; cell disorders; encodes
Prior art date: 2011-11-15

Application number

CL2014001263A

Other languages

Spanish (es)

Inventor

Eric Borges

Paul Adam

Peter Kufer

Tobias Raum

Patrick Hoffmann

Roman Kischel

Ralf Lutterbuese

Doris Rau

Barbara Hebeis

Susanne Hipp

Original Assignee

Boehringer Ingelheim Int

Amgen Res Munich Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-15

Filing date

2014-05-14

Publication date

2014-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52002373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-14 Application filed by Boehringer Ingelheim Int, Amgen Res Munich Gmbh filed Critical Boehringer Ingelheim Int

2014-10-10 Publication of CL2014001263A1 publication Critical patent/CL2014001263A1/en

Links

101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 2
208000023275 Autoimmune disease Diseases 0.000 title 1
208000037914 B-cell disorder Diseases 0.000 title 1
108091028043 Nucleic acid sequence Proteins 0.000 title 1
208000021161 Plasma cell disease Diseases 0.000 title 1
210000004027 cell Anatomy 0.000 title 1
230000002596 correlated effect Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
150000007523 nucleic acids Chemical group 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

CL2014001263A 2011-11-15 2014-05-14 Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases. CL2014001263A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date
US201161650149P	2011-11-15	2011-11-15
US201161560144P	2011-11-15	2011-11-15
US201161560178P	2011-11-15	2011-11-15
US201161560183P	2011-11-15	2011-11-15
US201161560162P	2011-11-15	2011-11-15
US201261651474P	2012-05-24	2012-05-24
US201261651486P	2012-05-24	2012-05-24

Publications (1)

Publication Number	Publication Date
CL2014001263A1 true CL2014001263A1 (en)	2014-10-10

Family

ID=52002373

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001263A CL2014001263A1 (en)	2011-11-15	2014-05-14	Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.

Country Status (1)

Country	Link
CL (1)	CL2014001263A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11434302B2 (en)	2016-02-03	2022-09-06	Amgen Research (Munich) Gmbh	Bispecific T cell engaging antibody constructs
US11447567B2 (en)	2015-07-31	2022-09-20	Amgen Research (Munich) Gmbh	Antibody constructs for FLT3 and CD3
US11884720B2 (en)	2015-07-31	2024-01-30	Amgen Research (Munich) Gmbh	Antibody constructs for MSLN and CD3

2014
- 2014-05-14 CL CL2014001263A patent/CL2014001263A1/en unknown

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11447567B2 (en)	2015-07-31	2022-09-20	Amgen Research (Munich) Gmbh	Antibody constructs for FLT3 and CD3
US11884720B2 (en)	2015-07-31	2024-01-30	Amgen Research (Munich) Gmbh	Antibody constructs for MSLN and CD3
US11434302B2 (en)	2016-02-03	2022-09-06	Amgen Research (Munich) Gmbh	Bispecific T cell engaging antibody constructs

Similar Documents

Publication	Publication Date	Title
CL2014001254A1 (en)	2014-10-10	Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
CY1122399T1 (en)	2020-11-25	COMPETITIVE TNF RECEPTOR BINDING FACTORS
CL2015000256A1 (en)	2015-07-03	Heteroaromatic compounds, btk inhibitors, pharmaceutical composition that comprises them and use in diseases such as rheumatoid arthritis, lupus, among others.
IL241332A0 (en)	2015-11-30	Bispecific binding molecules for bcma and cd3, compositions comprising same and uses thereof
AR090923A1 (en)	2014-12-17	ANTI-IL-23 ANTIBODIES
HK1206780A1 (en)	2016-02-12	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CL2013000338A1 (en)	2013-11-08	Binding protein that has the ability to bind interleukin 1beta and interleukin 17; crystallized binding protein conjugate; nucleic acid, vector, host cell; method to produce a binding protein; pharmaceutical composition comprising the binding protein.
AR090903A1 (en)	2014-12-17	ANTI-PMEL ANTIBODIES AND IMMUNOCADES17
EA201400579A1 (en)	2014-10-30	ANTIBODIES TO IL-36R
PE20190229A1 (en)	2019-02-13	ANTI-FCRN ANTIBODIES
WO2014182661A3 (en)	2015-01-08	Dosages and methods for delivering lipid formulated nucleic acid molecules
CL2015001570A1 (en)	2015-10-09	Method in a single container for the synthesis of cu-ssz-13, the compound obtained by means of the method and use thereof.
CL2014000631A1 (en)	2014-09-26	Binding molecule that binds to cd134 (ox40); nucleic acid molecule that encodes it; vector; host cell; Preparation process; pharmaceutical composition that includes it; and its use to treat cancer.
DK2963113T3 (en)	2020-02-17	PROCEDURE FOR ISOLATING SPECIFIC GENOMREGION USING MOLECULES BINDING SPECIFIC TO ENDOGENIC DNA SEQUENCE
BR112013029893A2 (en)	2017-05-30	cd3 binding molecule, cd3 binding antibody, cd3 binding antibody and pharmaceutical composition
IL230662A0 (en)	2014-03-31	Indazole-type substances, preparations containing these substances and their uses
EA201401077A1 (en)	2015-02-27	BISPECIFIC ANTIBODIES TO HUMAN TWEAK AND HUMAN IL17 AND THEIR APPLICATION
AR089528A1 (en)	2014-08-27	DUAL VARIABLE DOMAIN OF IMMUNOGLOBULINS AND THEIR USES
EA201490644A1 (en)	2014-09-30	THERAPEUTIC PEPTIDES
CL2011000730A1 (en)	2012-02-03	Selection procedure for anti-cxcr4 antibodies and selected antibodies; nucleic acid encoding the antibodies; vector; host cell; production procedure; hybridoma that produces the antibodies; composition; use of selected antibodies to prepare a medicine to treat cancer.
CL2014002072A1 (en)	2015-01-23	Cx3cr1 binding polypeptides; nucleic acid molecule that encodes it; pharmaceutical composition that contains it; method of elaboration of the peptide; uses of the peptide; kit containing the peptide.
NZ717399A (en)	2021-12-24	Antibodies against csf-1r
SI3200822T1 (en)	2021-10-29	Binding molecules, especially antibodies, binding to l1cam (cd171)
MX2016005956A (en)	2016-08-17	SPECIFIC ANTIBODIES FOR FCRN.
CL2014003167A1 (en)	2015-06-12	Binding molecule that specifically binds inteleukin 6 (il-6); pharmaceutical composition comprising it; nucleic acid; vector; host cell; and use to treat disease or disorder associated with il-6.